¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody deficiency disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® Buerger disease ÇÑ±Û ¹ö°Åº´
¼³¸í   
  ¸»ÃÊ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°´Â º´. Ã»Àå³âÃþÀÇ ³²ÀÚ¿¡°Ô Àß °É¸®´Â ´Ù¸® µ¿¸Æ¿¡ »ý±â´Â º´À¸·Î µ¿¸ÆÀÌ ¸·È÷°í ÅëÁõ ¶§¹®¿¡ ¹ßÀ» Àý±âµµ Çϴµ¥ ¿øÀÎÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. º´¸íÀº ÀÌ º´À» ÃÖÃʷΠ»ó¼¼ÇϰԠº¸°íÇÑ ¹Ì±¹ÀÇ ÀÇ»ç L. ¹ö°Å(1879~1943)ÀÇ À̸§¿¡¼­ ¿¬À¯ÇÑ´Ù. µ¿¾çÀο¡°Ô ¸¹Àº º´À¸·Î, ´ëºÎºÐ ÀþÀº ³²¼º, Æ¯È÷ Àå³â±â ³²¼º¿¡°Ô¼­ ³ªÅ¸³­´Ù. ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª Èí¿¬ÀÌ º´ÀÇ ¾ÇÈ­¸¦ ÃÊ·¡ÇÑ´Ù. »çÁöÀÇ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀÌ ÀϾ Ç÷ÀüÀÌ »ý±â¸é ³»°­À» ¸·¾Æ Ç÷¾×ÀÌ È帣Áö ¸øÇϰԠµÇ¾î ±× ¾ÕÀÇ ¸»ÃÊÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁö°Å³ª ¼Õ¹ßÀÌ Â÷°©°í, ¼Õ°¡¶ô-¹ß°¡¶ôÀÌ º¸¶ó»ö ¶Ç´Â °ËÀº»öÀ¸·Î º¯ÇÑ´Ù. ¶Ç, ÀÌ Áõ¼¼°¡ °è¼ÓµÇ´Â µ¿¾È ¼Õ¹ß°¡¶ô¿¡ ÅëÁõÀÌ ÀϾ°í ±Ë¾çÀÌ ¹ß»ýÇÑ´Ù. Ä¡·á´Â Áõ¼¼ÀÇ Á¤µµ¿Í Æó»öµÈ Ç÷°üÀÇ ºÎÀ§¿¡ µû¶ó ¿¬°í¸¦ ¹Ù¸£°Å³ª Ç÷°üÈ®ÀåÁ¦-¼øÈ¯°³¼±Á¦-Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦¸¦ »ç¿ëÇϳª, ¾î¶² Ä¡·áµµ È¿°ú°¡ ¾øÀ» °æ¿ì ¼Õ¹ß°¡¶ôÀÇ ¼ÒÀý´Ü, µå¹°°Ô´Â ¹«¸­ ÀÌÇÏÀÇ ´ëÀý´ÜÀ» ÇؾߠÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ º´ÀÇ ¿¹ÈĴ ¾çÈ£ÇÏ¿© Ç÷·ù°¡ È¸º¹µÇ°í ±Ë¾ç¸¸ Ä¡·áµÇ¸é Àç¹ßÀÌ Àû´Ù.
¿µ¹® Behcet disease ÇÑ±Û º£Ã¼Æ®º´
¼³¸í   
  ½ÉÇÑ Æ÷µµ¸·¿°, ¸Á¸·Ç÷°ü¿°, ½Ã°¢½Å°æÀ§Ãà, ±¸°­-¼º±âÀÇ ¾ÆÇÁŸ¼º ±Ë¾ç, ±¤¹üÀ§ÇÑ Ç÷°ü¿°ÀǠ¡ÈĿ͠Áõ»óÀ» ³ªÅ¸³½´Ù. ¿øÀκҸíÀÇ Èñ±ÍÇÑ º´À¸·Î ÀþÀº ³²ÀÚ¿¡°Ô Àß ¹ß»ýÇÑ´Ù.
¿µ¹® congenital heart disease ÇÑ±Û ¼±Ãµ½ÉÀ庴
¼³¸í   
  ¼±ÃµÀûÀ¸·Î ½ÉÀåÀÇ ±¸Á¶¿¡ ÀÌ»óÀÌ Àִ º´.
¿µ¹® venereal disease, sexually transmitted diseases ÇÑ±Û ¼ºº´
¼³¸í   
  º¸ÆíÀûÀ¸·Î ¼º±³ ¶Ç´Â ¼º±âÁ¢ÃË¿¡ ÀÇÇØ °É¸®´Â Á¢ÃË Àü¿°º´À¸·Î ¸Åµ¶, ÀÓÁú, ¹«¸¥±Ë¾ç, »ô±¼À°¾ÆÁ¾ µîÀ» ¸»ÇÑ´Ù. Ä¡·á´Â ¿øÀαտ¡ µû¸¥ ÀûÀýÇÑ Ç×»ý¿ä¹ýÀÌ´Ù.
¿µ¹® VDRL(venereal disease research laboratory) ÇÑ±Û ¼ºº´ ¿¬±¸½ÇÇè½Ç
¼³¸í   
  ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼­µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • anti-dsDNA antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antimitochondrial antibody
    Ç×¹ÌÅäÄܵ帮¾ÆÇ×ü, Ç׻縳üÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
  • anti-Ro antibody
    Ç×RoÇ×ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • de Quervain's disease
    µåÄõº£Àκ´
  • degenerative disease
    ÅðÇິ
  • fibrocystic disease
    ¼¶À¯³¶º´
  • glomerular disease
    Å丮º´, »ç±¸Ã¼Áúȯ
  • Hashimoto's disease
    ÇϽøðÅ亴
  • Hirschsprung's disease
    (¢¡ congenital megacolon) È÷¸£½´½´ÇÁ·îº´
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • infectious disease
    °¨¿°º´
  • inflammatory bowel disease
    ¿°ÁõâÀÚÁúȯ
  • inherited disease
    À¯Àüº´
  • Legg-Calve-Perthes disease
    (¢¡ostetochondrosis of the capitualar epiphysis of th) ·¹±×Ä®º£Æä¸£Å×½ºº´, ³Ò´Ù¸®»À¸Ó¸®»À³¡»À¿¬°ñÁõ
  • life style disease
    »ýȰ½À°üº´
  • metabolic disease
    ´ë»çº´, ´ë»çÁúȯ
  • mixed connective tissue disease
    È¥ÇÕ°áÇÕÁ¶Á÷º´
  • moyamoya disease
    ¸ð¾ß¸ð¾ßº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody removal
    Ç×üÁ¦°Å
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody transfer
    Ç×üÀÌÀÔ
  • antibody valence
    Ç×ü°áÇÕ°¡
  • antibody absorption
    Ç×üÈíÂø
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤¹ý
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀÓ±âÀü
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • galactosidase, alpha-galactosidase a, deficiency
    #NAME?
  • glucocerebrosidase deficiency
    ±Û·çÄÚ¼¼·¹ºê·Î½Ãµ¥À̽º °áÇÌÁõ
  • glucose 6 phosphatase deficiency hepa
    ±Û·çÄÚ¿À½º-6 -ÀÎ»ê °áÇ̰£½ÅÇü´ç
  • glucose-6-phosphate dehydrogenase deficiency
    ±Û·çÄÚ½º-6-ÀλêµðÇÏÀÌ µå·ÎÀú³×À̽º °áÇÌ(Áõ)
  • glutathione reductase deficiency
    ±Û·çŸƼ¿Â ȯ¿øÈ¿¼Ò °áÇÌÁõ.
  • glycosidase deficiency
    ±Û¸®ÄڽôپÆÁ¦°áÇÌ(Áõ).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
  • gonadal deficiency
    »ý½Ä¼±ºÎÀü(ßæãÖàÍÝÕîï).
  • hepatophosphorylase deficiency
    °£Æ÷½ºÆ÷¸±¶ó¾ÆÁ¦°áÇÌÁõ.
  • hexokinase deficiency
    Çí¼ÒÄ«À̳×À̽º°áÇÌ.
  • hexokinase deficiency
    Çí¼ÒŰ³ªÁ¦°áÇÌ.
  • hexosaminidase a deficiency
    Çí¼Ò»ç¹Ì´Ïµ¥À̽º A °áÇÌ(Áõ)
  • iduronate sulfatase deficiency
    Iduronate sulfatase deficiency
  • iga deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ
  • immunoglobulin A deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ(Áõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(Áõ)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(¡­ý£áÈÌÀù¹).
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • c3 deficiency
    C3 °áÇÌÁõ (¡­ÌÀù¹ñø)
  • carnitine palmitoyl transferase, deficiency
    Carnitine palmitoyl transferase, deficiency
  • cell adhesion molecular deficiency
    ¼¼Æ÷À¯ÂøºÐÀÚ°áÇÌ
  • cell deficiency (aganglionic megacolon)
    ¼¼Æ÷ÀÌÁÖ°áÇÌ (¹«½Å°æÀýÁÖ¸§Ã¢ÀÚ
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷(¸Å°³)¸é¿ª°áÇÌÁõÈıº.
  • cell mediated immunity deficiency syndrome
    ¼¼Æ÷¼º¸é¿ª°áÇÌÁõÈıº.
  • cellular deficiency (acallosal cerebrum)
    ¼¼Æ÷°áÇÌ (³úµéº¸°á¿©³ú)
  • chromosomal deficiency
    ¿°»öü°áÇÌ
  • coagulation factor deficiency
    ÀÀ°íÀÎÀÚ°áÇÌ
  • cobalamin deficiency
    Äڹ߶ó¹Î°áÇÌ
  • color vision deficiency
    »ö°¢ÀÌ»ó
  • combined immunity deficiency syndrome
    º¹Çո鿪°áÇÌÁõÈıº.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Hartnup's disease
    ÇÏÆ®³Ò Áúȯ(òðü´)
  • heavy-chain disease
    Áß(ñì)»ç½½ Áúȯ(òðü´)
  • Hers' disease
    ¿¡¸£½º Áúȯ(òðü´)
  • I-cell disease
    I-¼¼Æ÷ Áúȯ(á¬øàòðü´)
  • immune deficincy disease
    ¸é¿ª °áÇÌ Áúȯ(Øóæ¹ÌÀù¹òðü´)
  • Krabbe's disease
    Å©¶óº£Áúȯ(òðü´)
  • Kwok's disease
    °û Áúȯ(òðü´)
  • lipid storage disease
    ÁöÁúÀúÀåÁúȯ(ò·òõîÍíúòðü´)
  • lysosomal disease
    ¶óÀ̼ÒÁ»Áúȯ(òðü´)
  • lysosomal storage disease
    ¶óÀ̼ÒÁ»³»(Ò®) ÀúÀåÁúȯ(îÍíúòðü´)
  • maple syrup urine disease
    ´Üdz½Ã·´´¢Áúȯ(Òãòðü´)
  • metabolic disease
    ´ë»çÁúȯ(ÓÛÞóòðü´)
  • molecular disease
    ºÐÀÚº´(ÝÂí­Ü»)
  • mucopolysaccharide storage disease
    ¹ÂÄÚ´Ù´çÁú(ÒýÓØòõ)ÀúÀåÁúȯ(îÍíúòðü´)
  • Niemann-Pick disease
    ´Ï¸¸-ÇÈ Áúȯ(òðü´)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • granulomatous disease
    À°¾ÆÁ¾¼ºÁúȯ
  • Hand-Schueller-Christian disease
    ÇÚµå-½¯·¯-Å©¸®½ºÂùº´
  • Hashimoto's disease
    ÇϽøðÅ亴
  • hematopoietic disease
    Á¶Ç÷¼ºÁúȯ
  • hereditary disease
    À¯Àüº´
  • Hodgkin's disease
    È£ÁîŲº´
  • hyaline membrane disease
    À¯¸®Áú¸·º´
  • hypertensive vascular disease
    °íÇ÷¾Ð¼ºÇ÷°üÁúȯ
  • inherited disease
    À¯Àüº´
  • ischemic heart disease
    ÇãÇ÷¼º ½ÉÁúȯ
  • Letterer-Siwe disease
    ·¹Å×·¯-½Ã¿þº´
  • marble bone disease
    ´ë¸®¼®°ñº´
  • metabolic disease
    ´ë»ç¼ºÁúȯ
  • mitral valvular disease
    ½Â¸ðÆÇ¸·Áúȯ
  • neoplastic disease
    Á¾¾ç¼ºÁúȯ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CAD cadaver, cadaveric; cold agglutinin disease; compressed air disease; computer-assisted design; compu...
ID identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ...
ILD interstitial lung disease; intraoperative localization device; ischemic leg disease; ischemic limb d...
NSD Nairobi sheep disease; neonatal staphylococcal disease; neurosecretory dysfunction; night sleep depr...
CHD Chediak-Higashi disease; childhood disease; chronic hemodialysis; congenital or congestive heart dis...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GH-D GH deficiency
G6PD Glucose-6-Phosphate dehydrogenase deficiency
GKD Glycerol kinase deficiency
GHD Growth Hormone Deficiency
IgA-D IgA deficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mental deficiency
    Áö´É ¹Ú¾à, Áö´É ¹Ú¾àÁõ, Á¤½Å ¹Ú¾àÁõ
    ¿©·¯ °¡Áö ¿øÀο¡ ÀÇÇØ¼­ Áö´É ¹ß´ÞÀÌ Æò±Õº¸´Ù ³·°í Á¤½ÅÀû, ½ÅüÀû Àå¾Ö·Î ÀÎÇØ »çȸ »ýȰ¿¡ ´ëÇÑ ÀûÀÀÀÌ °ï¶õÇÑ »óÅÂ. Á¤½Å Áöü¶ó°íµµ ÇÑ´Ù. Çö´ë ÀÇÇп¡¼­´Â ÁøÇ༺ ¸¶ºñ¿¡ ÀÇÇÑ Ä¡¸Å³ª ÀϽÃÀûÀÎ Á¤½Å ±â´ÉÀÇ ÅðÇà°ú ±¸º°ÇÏ¿© Ç×±¸ÀûÀÎ Áöü »óŸ¦ ÀǹÌÇÑ´Ù. ¶ÇÇÑ ÀÏ¹Ý Áö´ÉÀÇ °áÇÔ¸¸ÀÌ ¾Æ´Ï¶ó '»çȸ »ýȰ¿¡¼­ÀÇ ½ÇõÀû Áö´É'À̶ó ºÎ¸¦ ¸¸ÇÑ Ãø¸é¿¡µµ ÁÖ¸ñÇÏ°Ô µÇ¸é¼­ Á¤½Å ¹Ú¾àÀÇ ºÐ·ù´Â »çȸÀÇ ÀûÀÀµµ¿Í »çȸÀû »ýȰ ´É·Â Á¤µµ¸¦ ¹èÇÕ½ÃŰ°Ô µÇ¾ú´Ù.
  • mineral deficiency
    ¹«±âÁú °áÇÌ, ¹«±âÁú °áÇÌÁõ
  • myeloperoxidase deficiency
    ¸¶ÀÌ¿¤·Î ÆÛ·Ï½Ãµ¥À̽º °áÇÌÁõ
    »ó¿°»öü¼º ¿­¼º ÇüÁú·Î À¯ÀüµÇ¸ç, Áß¼º±¸¿Í ´Ü±¸ÀÇ È£¾ÆÁÖ¸£¼º °ú¸³ ³»¿¡ MPO°¡ ÀüÇô ¾ø´Ù.
  • myoadenylate deaminase deficiency
    ¸¶ÀÌ¿À ¾Æµ¥´Ò·¹ÀÌÆ® µð¾Æ¹Ì³×À̽º °áÇÌÁõ
  • nutrition deficiency
    ¿µ¾ç °áÇÌÁõ
  • nutritional deficiency
    ¿µ¾ç °áÇÌ
  • plasma thromboplastin antecedent deficiency
    PTA °áÇÌÁõ
  • pyridoxine deficiency
    ÇǸ®µ¶½Å °áÇÌ
  • salt deficiency
    ¿°·ù °áÇÌ
  • sulfatase deficiency
    ¼³ÆÄÅ×À̽º °áÇÌ
  • vitamin B2 deficiency
    ºñŸ¹Î B2 °áÇÌÁõ
  • vitamin D deficiency
    ºñŸ¹Î D °áÇÌ, ºñŸ¹Î D °áÇÌÁõ
    ±¸·çº´-°ñ¿¬È­ÁõÀ¸·Î µî»À³ª °¡½¿»À µûÀ§°¡ ±Á´Â º´. °ö»çº´.
  • vitamin deficiency
    ºñŸ¹Î °áÇÌ, ºñŸ¹Î °áÇÌÁõ
    ¸é Á¾·ùÀÇ ½ÄǰÀ» ¼¯Àº º¸ÅëÀÇ ½Ä»ç¸¦ º¸Åë Á¶¸®¹ý¿¡ µû¶ó ¸ÔÀ» °æ¿ì´Â ºñŸ¹Î °áÇÌÁõÀÌ ³ªÅ¸³ªÁö ¾Ê´Â´Ù. ±×·¯³ª ¿¹¿Ü·Î½á ºñŸ¹Î D°áÇÌÁõÀº ÀÚÁÖ ³ªÅ¸³­´Ù. ½Äǰ Áß¿¡´Â ¿©·¯ Á¾·ùÀÇ ºñŸ¹ÎÀÌ °øÁ¸Çϰí Àֱ⠶§¹®¿¡ 1 Á¾·ù¸¸ÀÇ ºñŸ¹Î °áÇÌÁõº¸´Ùµµ ¿©·¯ Á¾·ùÀÇ ºñŸ¹Î °áÇÌÁõÀÌ ¸¹´Ù. ¼ÒÈ­±â Áúȯ¿¡ ¼ö¹ÝµÇ´Â Èí¼öÀå¾Ö, °¢Á¾ ¾àÀçÀÇ º¹¿ë¿¡ ÀÇÇÑ Àå³» ¼¼±ÕÃþÀÇ º¯È­, ü³»¿¡¼­ÀÇ ºñŸ¹Î Ȱ¼ºÈ­ÀÇ ÀúÇØ, »ý¸®Àû º¯È­¿¡ ´ëÀÀÇÑ ¿ä±¸·®ÀÇ Áõ°¡, °¨¿° µî¿¡ ÀÇÇØ °áÇÌÁõÀÌ ¹ß°ßµÇ´Â °æ¿ì°¡ ÀÖ´Ù. ±×·¯³ª ¾àÇÑ Á¤µµÀÇ °áÇÌÀÎ °æ¿ì¿¡´Â ÀüÇüÀû Áõ»óÀº º¸ÀÌÁö ¾ÊÀ¸¸ç, ÀÌ ¶§ÀÇ Áõ»óÀ» ºñŸ¹Î °¨¼ÒÁõÀ̶ó°í ÇÑ´Ù.
  • vitamin deficiency symptom
    ºñŸ¹Î °áÇÌÁõ
    ºñŸ¹ÎÀÇ ºÎÁ·À¸·Î ÀϾ´Â »ý¸® ±â´É Àå¾Ö. ¾ß¸ÍÁõ, °¢±âº´ µûÀ§°¡ ÀÖ´Ù.
  • vitamin I deficiency
    ºñŸ¹Î °áÇÌ, ºñŸ¹Î °áÇÌÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
antiphospholipid antibody syndrome <syndrome> An immune disorder characterised by the presence of abnormal antibodies in the blood associated with certain medical conditions including abnormal blood clotting, migraine headaches, premature miscarriage, and low blood platelet counts (thrombocytopenia).
(12 Dec 1998)
antithyroglobulin antibody <endocrinology, immunology> A serologic blood test which measures the antithyroglobulin antibodies in the blood. Thyroglobulin is a protein found in thyroid tissue. It is the source of thyroid hormones in the body.
The presence of antibodies to this protein can result in decreased thyroid gland function. A negative assay is considered normal.
Conditions where the assay may be positive include: lupus, rheumatoid arthritis, Hashimoto's thyroiditis, thyrotoxicosis, hypothyroidism, thyroid cancer, myxoedema, Sjogren's syndrome and autoimmune haemolytic anaemia.
(13 Jan 1998)
avidity antibody The sum total of the functional binding strength between a polyvariant and its antibody. The total binding strength represents the sum strength of all the affinity bonds.
(05 Mar 2000)
binding sites, antibody Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin.
(12 Dec 1998)
bivalent antibody Antibody that causes a visible reaction with specific antigen as in agglutination, precipitation, and so on; so-called because according to the "lattice theory" aggregation occurs when the antibody molecule has two or more binding sites that can crosslink one antigen particle to another; probably a characteristic of the class of immunoglobulin.
(05 Mar 2000)
blocking antibody An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor.
See: desensitisation.
(18 Nov 1997)
reaginic antibody <immunology> A type of antibody which is able to attach itself to the surfaces of cells without needing specific combining sites. A homocytotropic antibody will only bind to cells which are from the same species as itself.
(09 Oct 1997)
maternal antibody Any antibody transferred from a mammalian mother transplacentally into the foetus. See under immunoglobulin for details of the classes of Ig that are transferred to the foetus.
(18 Nov 1997)
catalytic antibody <chemistry> Antibody raised against a transition state analogue (e.g. A phosphate analogue of a carboxylic acid ester transition state) that can then catalyse the analogous chemical reaction, though not as effectively as a true enzyme.
(16 Mar 1998)
Vi antibody A form of antibody that agglutinates highly virulent strains of Salmonella typhi, i.e., cells with Vi antigen; such bacteria are not agglutinable with O antiserum until the Vi antigen is destroyed.
See: Vi antigen.
(05 Mar 2000)
cell-bound antibody A term used for antibody on the surface of cells that may be bound either through antigen combining sites or other sites such as the Fc region.
(05 Mar 2000)
CF antibody Antibody that combines with and sensitises antigen leading to the activation of complement, which may result in cell lysis.
Synonym: CF antibody, sensitizing substance.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • duck's disease
    (ÀÍ»ì)ªÀº ´Ù¸®
  • fishskin disease
    ¾î¸°¼±
  • footandmouth disease
    ¾Æ±¸Ã¢(°¡ÃàÀÇ ÀÔÀ̳ª ¹ß±Á¿¡ »ý±â´Â Àü¿°º´)
  • footinmouth disease
    ½Ç¾ðº®
  • green monkey disease
    =MARBURG DISEASE
  • heart disease
    ½ÉÀ庴
  • heart disease
    ½ÉÀ庴
  • hoof and mouth disease
    =FOOT AND MOUTH DISEASE
  • industrial disease
    (ÀÇ)Á÷¾÷º´
  • kashinBeck disease
    ij½Åº¤º´(À½·á¼ö ÁßÀÇ À¯±â»ê¿¡ ÀÇÇÑ »ÀÀÇ º¯Çü)
  • kissing disease
    Àü¿°¼º ´ÜÇÙÁõ;Ű½º º´
  • molecular disease
    ºÐÀÚº´
  • mosaic disease
    ¸ðÀÚÀÌÅ© º´(½Ä¹°ÀÇ Àü¿°º´)
  • occupational disease
    Á÷¾÷º´
  • parkinsons disease
    ÁøÀü ¸¶ºñ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á